TransMedics Group, Inc. (TMDX)Healthcare | Medical Devices | Andover, United States | NasdaqGM
76.52 USD
+1.00
(1.324%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 76.60 +0.08 (0.105%) ⇧ (Oct. 15, 2026, 5:05 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 5:36 a.m. EDT
The most critical signal here is the sharp divergence between the company's underlying financial health and its recent market performance. While the business generates impressive returns on equity of 36% and maintains robust revenue growth of 20%, the stock has suffered a significant technical breakdown, dropping over 11% in the last two weeks and trading well below its 50-day and 200-day moving averages. This short-term weakness is exacerbated by recent earnings misses, margin pressure headlines, and a serious legal investigation involving directors, which creates substantial near-term uncertainty and suppresses investor confidence. For the long term, the fundamentals remain compelling with a strong cash generation profile and a dominant position in medical devices, yet the high debt-to-equity ratio and governance concerns prevent a top-tier rating. The six-year price trajectory shows massive gains, but the recent annual decline suggests the market is re-pricing the risk profile. Consequently, the short-term outlook is bearish due to the momentum shift and legal overhang, while the long-term view remains cautiously positive, acknowledging the quality of the business but discounting for the execution and governance risks. There is no dividend income to offset these risks. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.118398 |
| AutoTheta | 0.120522 |
| AutoARIMA | 0.121482 |
| AutoETS | 0.121482 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.58 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.820 |
| Excess Kurtosis | -0.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 167.496 |
| Revenue per Share | 19.474 |
| Market Cap | 2,644,600,832 |
| Trailing P/E | 20.51 |
| Forward P/E | 33.95 |
| Beta | 1.93 |
| Profit Margins | 22.69% |
| Website | https://www.transmedics.com |
As of Oct. 10, 2026, 5:36 a.m. EDT: Implied volatility remains elevated across expirations, ranging from 55% to 90% at-the-money, reflecting heightened uncertainty. Open interest concentrations are visible at lower strikes ($65-$80) for puts, indicating defensive positioning against further downside, while call open interest builds significantly at $100-$125 strikes, suggesting speculative bets on a recovery. Recent volume spikes occurred at the $80 call strike and $76 put strike, aligning with the recent price dip and potential support/resistance testing.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.35798693 |
| Address1 | 200 Minuteman Road |
| Address2 | Suite 302 |
| All Time High | 177.37 |
| All Time Low | 10.0 |
| Ask | 87.47 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 872,370 |
| Average Daily Volume3 Month | 822,166 |
| Average Volume | 822,166 |
| Average Volume10Days | 872,370 |
| Beta | 1.926 |
| Bid | 55.39 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 14.96 |
| City | Andover |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 76.52 |
| Current Ratio | 6.625 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 77.34 |
| Day Low | 74.86 |
| Debt To Equity | 167.496 |
| Display Name | TransMedics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,875,400 |
| Earnings Call Timestamp Start | 1,785,875,400 |
| Earnings Growth | -0.558 |
| Earnings Quarterly Growth | -0.579 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,304,000 |
| Earnings Timestamp Start | 1,793,304,000 |
| Ebitda | 115,629,000 |
| Ebitda Margins | 0.17298001 |
| Enterprise To Ebitda | 26.364 |
| Enterprise To Revenue | 4.56 |
| Enterprise Value | 3,048,387,072 |
| Eps Current Year | 1.513 |
| Eps Forward | 2.25415 |
| Eps Trailing Twelve Months | 3.73 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 85.6188 |
| Fifty Day Average Change | -9.098801 |
| Fifty Day Average Change Percent | -0.106271066 |
| Fifty Two Week Change Percent | -35.79869 |
| Fifty Two Week High | 156.0 |
| Fifty Two Week High Change | -79.48 |
| Fifty Two Week High Change Percent | -0.5094872 |
| Fifty Two Week Low | 60.105 |
| Fifty Two Week Low Change | 16.414997 |
| Fifty Two Week Low Change Percent | 0.27310535 |
| Fifty Two Week Range | 60.105 - 156.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,556,803,800,000 |
| Float Shares | 33,559,299 |
| Forward Eps | 2.25415 |
| Forward P E | 33.946278 |
| Free Cashflow | 44,496,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 898 |
| Fullday Change | 1.0300064 |
| Fullday Change Percent | 1.3638856 |
| Fullday Price | 76.52 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.58694 |
| Gross Profits | 392,348,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03642 |
| Held Percent Institutions | 1.02948 |
| Implied Shares Outstanding | 34,560,911 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. |
| Long Name | TransMedics Group, Inc. |
| Market | us_market |
| Market Cap | 2,644,600,832 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_429233 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 151,699,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,016,737,615 |
| Number Of Analyst Opinions | 11 |
| Open | 75.07 |
| Operating Cashflow | 145,928,000 |
| Operating Margins | 0.124960005 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.65 |
| Phone | 978 552 0900 |
| Post Market Change | 0.08000183 |
| Post Market Change Percent | 0.10455023 |
| Post Market Price | 76.6 |
| Post Market Time | 1,792,098,325 |
| Previous Close | 75.52 |
| Price Eps Current Year | 50.575012 |
| Price Hint | 2 |
| Price To Book | 5.114973 |
| Price To Sales Trailing12 Months | 3.9562118 |
| Profit Margins | 0.22694 |
| Quick Ratio | 5.869 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.84615 |
| Region | US |
| Regular Market Change | 1.0 |
| Regular Market Change Percent | 1.32415 |
| Regular Market Day High | 77.34 |
| Regular Market Day Low | 74.86 |
| Regular Market Day Range | 74.86 - 77.34 |
| Regular Market Open | 75.07 |
| Regular Market Previous Close | 75.52 |
| Regular Market Price | 76.52 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 1,139,458 |
| Return On Assets | 0.043319996 |
| Return On Equity | 0.36285 |
| Revenue Growth | 0.207 |
| Revenue Per Share | 19.474 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 34,560,911 |
| Shares Percent Shares Out | 0.2466 |
| Shares Short | 8,551,869 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 8,079,087 |
| Short Name | TransMedics Group, Inc. |
| Short Percent Of Float | 0.384 |
| Short Ratio | 11.71 |
| Source Interval | 15 |
| State | MA |
| Symbol | TMDX |
| Target High Price | 125.0 |
| Target Low Price | 65.0 |
| Target Mean Price | 98.72727 |
| Target Median Price | 100.0 |
| Total Cash | 472,675,008 |
| Total Cash Per Share | 13.632 |
| Total Debt | 867,720,000 |
| Total Revenue | 668,467,968 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 3.73 |
| Trailing P E | 20.514744 |
| Trailing Peg Ratio | 0.7452 |
| Triggerable | 1 |
| Two Hundred Day Average | 98.13283 |
| Two Hundred Day Average Change | -21.612831 |
| Two Hundred Day Average Change Percent | -0.22024058 |
| Type Disp | Equity |
| Volume | 1,139,458 |
| Website | https://www.transmedics.com |
| Zip | 1,810 |